Search

Displaying results 3531 - 3540 of 5263 in total
  1. Drug

    Fluvastatin

    go.drugbank.com/drugs/DB01095
    ApprovedInvestigational

    It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class.

  2. Drug

    Poa pratensis pollen

    go.drugbank.com/drugs/DB10366
    Approved

    Poa pratensis pollen is the pollen of the Poa pratensis plant. Poa pratensis pollen is mainly used in allergenic testing.

  3. Drug

    Implitapide

    go.drugbank.com/drugs/DB04852
    Investigational

    Implitapide is a microsomal triglyceride transfer protein (MTP)-inhibitor.

  4. Drug

    Bisphosphocin Nu-3

    go.drugbank.com/drugs/DB16015
    Investigational

    Bisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).

    Synonyms: Nu-3, Bisphosphocin Nu-3
  5. Drug

    V-SARS

    go.drugbank.com/drugs/DB15812
    Investigational

    [COVID-19 convalescent plasma] is currently being acquired from recovered COVID-19 patients and used as prophylaxis for the virus. … This therapeutic concept was applied to the development of V-SARS, which heat inactivates the plasma, and packages it into a once-daily pill form.

  6. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

  7. Drug

    Ceritinib

    go.drugbank.com/drugs/DB09063
    ApprovedInvestigational

    Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells

    Synonyms: N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide
  8. Drug

    RPI-78M

    go.drugbank.com/drugs/DB05740
    Experimental

    Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).

  9. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

  10. Drug

    Dengue virus serotype 1

    go.drugbank.com/drugs/DB22664
    Approved

    [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.